2020
Prognostic Models in Myelodysplastic Syndromes
Bewersdorf J, Zeidan A. Prognostic Models in Myelodysplastic Syndromes. 2020, 109-127. DOI: 10.1007/978-3-030-51878-3_7.Peer-Reviewed Original ResearchInternational Prognostic Scoring SystemRisk stratification toolMyelodysplastic syndromeScoring systemStratification toolPrognostic scoring systemClinical trial enrollmentTrial enrollmentPrognostic relevanceDisease characteristicsPatient counselingBody of evidenceTreatment recommendationsPatient subpopulationsIndividual patientsTreatment selectionClinical scenariosPrognostic modelGenetic testingSomatic mutationsSyndromeScoresPatientsPrognostication
2017
A call for action: Increasing enrollment of untreated patients with higher‐risk myelodysplastic syndromes in first‐line clinical trials
Zeidan AM, Stahl M, Sekeres MA, Steensma DP, Komrokji RS, Gore SD. A call for action: Increasing enrollment of untreated patients with higher‐risk myelodysplastic syndromes in first‐line clinical trials. Cancer 2017, 123: 3662-3672. PMID: 28759108, DOI: 10.1002/cncr.30903.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHigh-risk myelodysplastic syndromeAZA-001 trialClinical trialsMinimal survival gainsLarge randomized trialsManagement of patientsPopulation-based studyClinical trial enrollmentQuality of lifeMonotherapy armMedian survivalRandomized trialsSurvival impactTrial enrollmentSurvival gainMyelodysplastic syndromeRegistry analysisAggressive malignancyPatientsNatural historyRoutine useTrialsSurvivalEnrollmentHMAs